QBECO

DRUG2 trials

Sponsors

Qu Biologics Inc., Sunnybrook Health Sciences Centre

Conditions

Colorectal CancerCrohn's DiseaseInflammatory Bowel DiseaseLiver Metastases

Phase 1

Safety and Treatment Effect of QBECO in Moderate to Severe Crohn's Disease

CompletedNCT01809275

Qu Biologics Inc.Crohn's Disease, Inflammatory Bowel Disease

Start: 2013-03-31End: 2016-07-31Updated: 2016-08-23

Phase 2

A Study of QBECO Versus Placebo in the Treatment of Colorectal Cancer That Has Spread to the Liver

Active, not recruitingNCT05677113

Sunnybrook Health Sciences CentreColorectal Cancer, Liver Metastases

Start: 2023-08-01End: 2031-02-01Target: 115Updated: 2026-08-21

Related Papers

Novel Microbial-Based Immunotherapy Approach for Crohn's Disease

Frontiers in Medicine2019-07-199 citations

P047 HISTOLOGICAL AND ENDOSCOPIC HEALING AFTER QBECO TREATMENT IN AN OPEN-LABEL PHASE 2 STUDY IN PATIENTS WITH ULCERATIVE COLITIS

Inflammatory Bowel Diseases2018-01-18